Skip to main content
PolicySpeak
← All files
MGF

medac Gesellschaft für klinische Spezialpräparate mbH

Company · Germany · EU Transparency Register 526758452908-81

2
positions filed
in the 326 files tracked
2
legislative files
of 326 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #454 by legislative files engaged — a count of participation, not a measure of influence.

1
declared lobbying FTE
self-declared
€50K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2024
in the register since

Declares membership of

  • European Confederation of Pharmaceutical Entrepreneurs AISBL (https://www.eucope.org)
  • Bundesverband der Pharmazeutischen Industrie e.V. (https://www.bpi.de)
  • VDGH - Verband der Diagnostica-Industrie e.V. (https://www.vdgh.de)

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Registered as
Medac Gesellschaft für klinische Spezialpräparate m.b.H. (medac)
Head office
Wedel, Germany

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track medac in PolicySpeak: request access →

Work at medac Gesellschaft für klinische Spezialpräparate mbH? so we know who speaks for it.

Follow the files medac Gesellschaft für klinische Spezialpräparate mbH engages with

One email on Tuesdays when a new position is filed on these 2 files, from medac Gesellschaft für klinische Spezialpräparate mbH or from anyone else on them. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

medac Gesellschaft für klinische Spezialpräparate mbH filed 2 positions between 11 Jun 2025 and 6 Oct 2025, across 2 of the 326 legislative files tracked here.

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025source

MEDAC is a German-based pharmaceutical company with cancer and autoimmune medicines, but also has a medical technology and diagnostics business. medac therefore welcomes the European Commission’s ambition to streamline and future-proof the regulatory framework by reducing administrative burdens and increasing predictability and cost-effectiveness.

Filed in German · English published by the European Commission

European Biotech Actfiled 11 Jun 2025source

MEDAC is a German-based pharmaceutical company with production sites in Germany and Czechia, which, in addition to medicines with conventional chemical manufacturing processes, also develops, manufactures and distributes biotechnological drugs for cancer and autoimmune diseases.

Filed in German · English published by the European Commission

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.

Showing 5 of 44.

Is this your organization?

Everything on this page comes from medac Gesellschaft für klinische Spezialpräparate mbH’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.